CMPSN Stock Chart & Stats
$241.00
-$31.00(-12.81%)
At close: 4:00 PM EDT
$241.00
-$31.00(-12.81%)
Day’s Range― - ―
52-Week Range$85.00 - $260.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$33.75B
Enterprise Value$1.53K
Total Cash (Recent Filing)$433.30M
Total Debt (Recent Filing)$54.63M
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Oct 29, 2026EPS Estimate
-6.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.57
Shares Outstanding138,476,820
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-12.21
Price to Sales (P/S)0.00
P/FCF Ratio-4.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$406.67Price Target Upside68.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-38.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable Phase 3 Efficacy And SafetyExtended 52-week data strengthen evidence that COMP360 can deliver meaningful and durable benefit beyond an initial treatment response. Consistent safety findings and response across follow-up support regulatory confidence, differentiation in treatment-resistant depression, and a potentially durable clinical value proposition.
Regulatory Progress And Launch ReadinessAn active rolling NDA with modules already under review reduces the distance to a potential commercial milestone and demonstrates advancing execution. The defined filing and launch timetable also allows the company to align commercial hiring, reimbursement planning, training, and site preparation around a credible development path.
Cash Runway And Low LeverageThe substantial cash position and very low debt burden provide financial capacity to continue late-stage development and prepare for launch without immediate heavy reliance on debt. This runway gives management flexibility to pursue regulatory and commercial execution while limiting near-term balance-sheet pressure.
Bears Say
Pre-revenue Model With Widening LossesCOMPASS remains dependent on successful clinical development and future approval because it has no reported revenue to offset substantial operating costs. Widening losses and persistent cash burn consume financial resources, increase dependence on capital availability, and could constrain investment if commercialization takes longer than planned.
Regulatory And Reimbursement Timing UncertaintyEven with positive clinical results, patient access depends on several external processes that may not align with the targeted launch schedule. Delays in rescheduling, REMS finalization, or payer negotiations could defer revenue generation, slow site activation, and increase the resources required to convert approval into broad adoption.
Balance-sheet And Shareholder Cushion InstabilityThe history of negative and volatile equity indicates that the reported cash balance has not translated into consistently stable shareholder capital. Although current leverage is low, continued losses and funding dependence could require additional capital and create dilution or financial flexibility risks during the commercialization period.
COMPASS Pathways News
CMPSN FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was $85.00 and its highest was $260.00 in the past 12 months.
What is COMPASS Pathways’s market cap?
COMPASS Pathways’s market cap is $33.75B.
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is Oct 29, 2026 which is in 45 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Aug 05, 2026. The company reported -$32.234 earnings per share for the quarter, missing the consensus estimate of -$6.653 by -$25.582.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -6.22.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 138,476,820 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -$32.234 in its last earnings report, missing expectations of -$6.653. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Currently, no hedge funds are holding shares in MX:CMPSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$406.67 (68.74% Upside)
$406.67 (68.74% Upside)
Blogger Sentiment
Bullish
MX:CMPSN Sentiment 98%
Sector Average 62%
Sector Average 62%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
173.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
71.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
COMPASS Pathways
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
CMPSN Company Deck
CMPSN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and commercial momentum: highly statistically significant Phase III efficacy, demonstrated 6-month durability, a generally favorable safety profile, an active rolling NDA with modules under review, a healthy cash position ($433M) through 2028, extensive commercial hiring, strong prescriber interest (~90% willing to prescribe), and substantial launch planning (training, payer engagement, partnerships). Key risks highlighted are timing and sequencing uncertainties around DEA rescheduling and REMS finalization, ongoing payer negotiations, remaining 52-week safety data submission, and potential competitive entrants. On balance, the positive clinical results and robust launch preparedness materially outweigh the timing and regulatory uncertainties.View all MX:CMPSN earnings summariesCMPSN Stock 12 Month Forecast
Average Price Target
$406.67
▲(68.74% Upside)